CD44 and prostate carcinoma: However, in the human prostate cancer cell line PC3, CD44 and integrin α2β1 were found to be expressed on essentially all PC3 cells [3,12], indicating a need to identify other, more robust CSC markers in this widely studied model for advanced, androgen-independent metastatic prostate cancer [29,30].